PSMA-Targeted PET Imaging for Prostate Cancer

Better Edge : A Northwestern Medicine podcast for physicians

English - August 18, 2021 05:00 - 17.2 MB - ★★★★★ - 2 ratings
Health & Fitness northwestern medicine better edge research Homepage Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed

Previous Episode: Managing Treatment Related Cardiovascular Side Effects

Next Episode: How to Avoid Neuro-ophthalmic Catastrophes: Safe not Sorry

The FDA recently approved PSMA PET imaging agent 18F-DCFPyL (Pylarify) for identifying suspected metastasis or recurrence of prostate cancer. Northwestern Memorial Hospital is the first site in the Chicagoland market to perform prostate imaging using the this agent. What makes this approval so exciting, how will it change the field? How will it improve the diagnosis and treatment of prostate cancer patients?

Edward Schaeffer MD, PhD, Ashley Ross MD, PhD and Hatice Savas MD discuss PET PSMA imaging for prostate cancer the recent FDA approval of Pylarify for prostate cancer detection.